LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Actinium Pharmaceuticals Inc

Closed

1.67 9.87

Overview

Share price change

24h

Current

Min

1.62

Max

1.68

Key metrics

By Trading Economics

Income

-9.3M

-16M

EPS

-0.51

Employees

31

EBITDA

5.1M

-7.3M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+259.28% upside

Dividends

By Dow Jones

Next Earnings

1 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-8.1M

48M

Previous open

-8.2

Previous close

1.67

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 May 2025, 19:39 UTC

Major Market Movers

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

17 May 2025, 09:30 UTC

Top News
Earnings

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 May 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 May 2025, 08:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

17 May 2025, 05:30 UTC

Acquisitions, Mergers, Takeovers

Tradeweb Is Looking to Come to a Bond Market Near You -- Barrons.com

16 May 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 May 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16 May 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 May 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 May 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 May 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 May 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 May 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 May 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 May 2025, 20:55 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 May 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

16 May 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 May 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 May 2025, 20:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 May 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 May 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 May 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 May 2025, 20:15 UTC

Earnings

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 May 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: William K. Daniel Joins Board

16 May 2025, 20:10 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: Strategic Investment by KKR Completed

16 May 2025, 20:05 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 May 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 May 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 May 2025, 18:51 UTC

Top News

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 May 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

259.28% upside

12 Months Forecast

Average 6 USD  259.28%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.